Abbott Launches First Ready-to-Feed Whole Milk Infant Formula, Addressing Nutrition Volume Declines

What happened

Abbott Laboratories announced the U.S. launch of Similac 360 Total Care Made With Whole Milk, the first ready-to-feed liquid infant formula made with whole milk. The product is priced at a similar per-feeding cost to Abbott's existing powdered Similac 360 Total Care and is available online and at major retailers. The launch targets growing parental preference for whole milk formulas and offers the convenience of commercially sterile ready-to-feed format. This move comes as Abbott's Nutrition segment continues to struggle, with first-half 2026 sales down 5.6% ex-FX and Q2 comparable sales down 3.6% on lower volumes. While the new formula could help stabilize pediatric nutrition sales, it does not address adult nutrition weakness or the broader volume declines driven by pricing actions.

Implication

In the short term, the ready-to-feed formula may attract some consumers seeking whole milk options, but adoption rates and retail shelf space are uncertain, so financial impact is likely limited in the next few quarters. The product launch does not address the adult nutrition category, which has also been a drag, and the company's pricing strategy may still be suppressing volumes across the segment. Investors should monitor whether the new formula gains market share and contributes to nutrition stabilization, as the current investment thesis requires nutrition to stop declining. If successful, the product could improve Abbott's competitive position in the premium infant formula market, but it may also increase manufacturing complexity and costs. Overall, this news is not enough to change the WAIT rating; the stock remains fairly valued at 34.5x earnings with execution risks tied to devices, Libre quality, and Exact Sciences integration.

Thesis delta

The launch of a whole milk ready-to-feed formula is a targeted response to nutrition volume declines and could support the pediatric portion of the segment. However, it does not alter the core concerns about adult nutrition weakness or the need for broader nutrition stabilization. Therefore, the investment thesis of waiting for better entry and clearer evidence of nutrition recovery remains unchanged.